<cite id="uufuy"><noscript id="uufuy"></noscript></cite>
    <rp id="uufuy"></rp>

    A 30 YEAR JOURNEY
    WITH A RELENTLESS
    FOCUS ON SCIENCE

    OUR HISTORY

    1988

    Leonard S. Schleifer, MD, PhD: Founder of Regeneron

    Regeneron is founded by Leonard S. Schleifer, MD, PhD, young neurologist and assistant professor at Cornell University Medical College

    1989

    George D. Yancopoulos, MD, PhD a molecular immunologist lauched Regeneron in 1989.

    George D. Yancopoulos, MD, PhD, a highly regarded young molecular immunologist at Columbia University, launches Regeneron

    1990

    Science publishes our first paper in 1990, which becomes the most highly cited neurobiology paper of the year.

    Science publishes our first paper, which becomes the most highly cited neurobiology paper of the year

    We announce a collaboration to develop neurotrophic factors

    1991

    REGN stock begins trading publicly on the NASDAQ in 1991

    REGN stock begins trading publicly on the NASDAQ; the Initial Public Offering raises $91.6 million

    1992

    Clinical development of Regeneron's first investigational drug began in 1992.

    Clinical development of our first investigational drug, a neurotrophic factor, begins

    1993

    Regeneron acquired space for a drug manufacturing facility in 1993.

    We acquire space for a drug manufacturing facility in Rensselaer, NY, years before having an FDA-approved product

    1995

    P. Roy Vagelos, MD becomes Chairman of the Board in 1995.

    Industry legend P. Roy Vagelos, MD, becomes Chairman of the Board, a position he still holds today

    Dr. Vagelos, another businessman-scientist who had previously led Merck's R&D division, encourages us to focus our research on disease settings where the biological profile can be fully characterized and the clinical benefit evaluated more quickly

    1997

    Phase 3 trial of first neurotrophic factor does not achieve primary endpoint in 1997.

    The Phase 3 trial of our first neurotrophic factor does not achieve its primary endpoint, and though the team is disappointed, we regroup to focus on new therapeutic solutions

    1999

    George Yancopoulos, MD, PhD becomes 11th most highly cited scientists in 1999.

    George Yancopoulos, MD, PhD, becomes the decade's 11th most highly cited scientist in the world

    2000

    ARCALYST injection begins clinical exploration in 2000.

    ARCALYST? (rilonacept) Injection, our first Trap technology, begins clinical exploration

    2003

    First paper on VelociGene? is published in 2003.

    Our first paper on VelociGene? is published, introducing the world to our proprietary Veloci technologies

    We become one of the original sponsors of the Westchester Science & Engineering Fair (WESEF) to support and reward scientific excellence in promising high school students

    2004

    EYLEA injection begins clinical development in 2004.

    EYLEA? (aflibercept) Injection begins clinical development

    2006

    Regeneron's first fully human antibody enters clinical development in 2006.

    A collaboration with Bayer HealthCare focuses on developing EYLEA? (aflibercept) Injection outside the U.S.

    Sarilumab, our first fully human antibody, enters clinical development

    2007

    Collaboration with Sanofi using VelocImmune? technology platform in 2007

    A collaboration with Sanofi focuses on developing fully human antibodies using our VelocImmune? technology platform

    2008

    FDA approval of ARCALYST injection in 2008

    The FDA approves our first medicine, ARCALYST? (rilonacept) Injection

    2009

    Regeneron hires its 1000th employee in 2009.

    We expand and extend our antibody collaboration with Sanofi

    PRALUENT? (alirocumab) Injection begins clinical development

    We hire our 1,000th employee and move into new buildings on our Tarrytown campus

    2010

    Regeneron begins to sponsor BioBus in 2010.

    We begin sponsorship of the BioBus, a mobile laboratory, to drive hands-on science education in underserved school districts

    2011

    EYLEA Injection is FDA approved in 2011.

    The FDA approves EYLEA? (aflibercept) Injection for its first indication

    Our President and CEO, Leonard S. Schleifer, is named Ernst & Young's 2011 New York Entrepreneur Of The Year?

    2012

    Named biotech company of the year in 2012

    The Science Top Employer survey names us the #1 employer in the global biopharmaceutical industry

    Scrip Intelligence names us Biotech Company of the Year

    2013

    Regeneron office opens in Dublin, Ireland in 2013.

    We announce the first recipients of our annual Regeneron Prize for Creative Innovation

    Our European business office opens in Dublin, Ireland

    Scrip Intelligence names Len and George as the "Management Team of the Year"

    2014

    Regeneron Genetics Center launches in 2014.

    The Regeneron Genetics Center, a new human genetics initiative, officially launches

    The FDA grants investigational antibody dupilumab Breakthrough Therapy designation

    We initiate the STEM Teaching Fellowship, a joint effort with the STEM Leadership Center, to develop a highly trained science teacher community, and Sci2Med Academy in collaboration with Yonkers Partners in Education to broaden career horizons for students who are underrepresented in the science fields

    We begin building our first ex-U.S. IOPS site in Limerick, Ireland

    2015

    PRALUENT Injection received FDA approval in 2015.

    The FDA approves PRALUENT? (alirocumab) Injection, our fourth FDA-approved medicine and first FDA-approved fully human monoclonal antibody

    We launch a major new immuno-oncology collaboration with Sanofi

    We enter into an agreement with the U.S. government for the development of a new antibody treatment for the Ebola virus

    2016

    Regeneron becomes new title sponsor for the Science Talent Search in 2016.

    We are named as the new title sponsor for the Science Talent Search (just the third in the prestigious competition's 75-year history)

    2017

    DUPIXENT Injection is FDA approved in 2017.

    KEVZARA Injection is FDA approved in 2017.

    The FDA approves DUPIXENT? (dupilumab) Injection, our fifth FDA-approved medicine

    FDA approves KEVZARA? (sarilumab) Injection, our sixth FDA-approved medicine and second fully human monoclonal antibody

    Recognized on the Civic 50 list of most community-minded companies in the United States

    2018

    Libtayo Injection receives FDA approval in 2018.Libtayo Injection receives FDA approval in 2018.DUPIXENT Injection is FDA approved for a new indication in 2018.

    2018 marks the thirtieth anniversary of Regeneron’s founding

    FDA approves Libtayo? (cemiplimab-rwlc) Injection, our seventh FDA-approved medicine

    The FDA approves a new indication for DUPIXENT? (dupilumab) Injection

    OUR HISTORY

    1988

    Leonard S. Schleifer, MD, PhD: Founder of Regeneron

    Regeneron is founded by Leonard S. Schleifer, MD, PhD, young neurologist and assistant professor at Cornell University Medical College

    1989

    George D. Yancopoulos, MD, PhD a molecular immunologist lauched Regeneron in 1989.

    George D. Yancopoulos, MD, PhD, a highly regarded young molecular immunologist at Columbia University, launches Regeneron

    1990

    Science publishes our first paper in 1990, which becomes the most highly cited neurobiology paper of the year.

    Science publishes our first paper, which becomes the most highly cited neurobiology paper of the year

    We announce collaboration to develop neurotrophic factors

    1991

    REGN stock begins trading publicly on the NASDAQ in 1991

    REGN stock begins trading publicly on the NASDAQ; the Initial Public Offering raises $91.6 million

    1992

    Clinical development of Regeneron's first investigational drug began in 1992.

    Clinical development of our first investigational drug, a neurotrophic factor, begins

    1993

    Regeneron acquired space for a drug manufacturing facility in 1993.

    We acquire space for a drug manufacturing facility in Rensselaer, NY, years before having an FDA-approved product

    1995

    P. Roy Vagelos, MD becomes Chairman of the Board in 1995.

    Industry legend P. Roy Vagelos, MD, becomes Chairman of the Board, a position he still holds today

    Dr. Vagelos, another businessman-scientist who had previously led Merck's R&D division, encourages us to focus our research on disease settings where the biological profile can be fully characterized and the clinical benefit evaluated more quickly

    1997

    Phase 3 trial of first neurotrophic factor does not achieve primary endpoint in 1997.

    The Phase 3 trial of our first neurotrophic factor does not achieve its primary endpoint, and though the team is disappointed, we regroup to focus on new therapeutic solutions

    1999

    George Yancopoulos, MD, PhD becomes 11th most highly cited scientists in 1999.

    George Yancopoulos, MD, PhD, becomes the decade's 11th most highly cited scientist in the world

    2000

    ARCALYST injection begins clinical exploration in 2000.

    ARCALYST? (rilonacept) Injection, our first Trap technology, begins clinical exploration

    2003

    First paper on VelociGene? is published in 2003.

    Our first paper on VelociGene? is published, introducing the world to our proprietary Veloci technologies

    We become one of the original sponsors of the Westchester Science & Engineering Fair (WESEF) to support and reward scientific excellence in promising high school students

    2004

    EYLEA injection begins clinical development in 2004.

    EYLEA? (aflibercept) Injection begins clinical development

    2006

    Regeneron's first fully human antibody enters clinical development in 2006.

    A collaboration with Bayer HealthCare focuses on developing EYLEA? (aflibercept) Injection outside the U.S.

    Sarilumab, our first fully human antibody, enters clinical development

    2007

    Collaboration with Sanofi using VelocImmune? technology platform in 2007

    A collaboration with Sanofi focuses on developing fully human antibodies using our VelocImmune? technology platform

    2008

    FDA approval of ARCALYST injection in 2008

    The FDA approves our first medicine, ARCALYST? (rilonacept) Injection

    2009

    Regeneron hires its 1000th employee in 2009.

    We expand and extend our antibody collaboration with Sanofi

    PRALUENT? (alirocumab) Injection begins clinical development

    We hire our 1,000th employee and move into new buildings on our Tarrytown campus

    2010

    Regeneron begins to sponsor BioBus in 2010.

    We begin sponsorship of the BioBus, a mobile laboratory, to drive hands-on science education in underserved school districts

    2011

    EYLEA Injection is FDA approved in 2011.

    The FDA approves EYLEA? (aflibercept) Injection for its first indication

    Our President and CEO, Leonard S. Schleifer, is named Ernst & Young's 2011 New York Entrepreneur Of The Year?

    2012

    Named biotech company of the year in 2012

    The Science Top Employer survey names us the #1 employer in the global biopharmaceutical industry

    Scrip Intelligence names us Biotech Company of the Year

    2013

    Regeneron office opens in Dublin, Ireland in 2013.

    We announce the first recipients of our annual Regeneron Prize for Creative Innovation

    Our European business office opens in Dublin, Ireland

    Scrip Intelligence names Len and George as the "Management Team of the Year"

    2014

    Regeneron Genetics Center launches in 2014.

    The Regeneron Genetics Center, a new human genetics initiative, officially launches

    The FDA grants investigational antibody dupilumab Breakthrough Therapy designation

    We initiate the STEM Teaching Fellowship, a joint effort with the STEM Leadership Center, to develop a highly trained science teacher community, and Sci2Med Academy in collaboration with Yonkers Partners in Education to broaden career horizons for students who are underrepresented in the science fields

    We begin building our first ex-U.S. IOPS site in Limerick, Ireland

    2015

    PRALUENT Injection received FDA approval in 2015.

    The FDA approves PRALUENT? (alirocumab) Injection, our fourth FDA-approved medicine and first FDA-approved fully human monoclonal antibody

    We launch a major new immuno-oncology collaboration with Sanofi

    We enter into an agreement with the U.S. government for the development of a new antibody treatment for the Ebola virus

    2016

    Regeneron becomes new title sponsor for the Science Talent Search in 2016.

    We are named as the new title sponsor for the Science Talent Search (just the third in the prestigious competition's 75-year history)

    2017

    DUPIXENT Injection is FDA approved in 2017.

    The FDA approves DUPIXENT? (dupilumab) Injection, our fifth FDA-approved medicine

    FDA approves KEVZARA? (sarilumab) Injection, our sixth FDA-approved medicine and second fully human monoclonal antibody

    Recognized on the Civic 50 list of most community-minded companies in the United States

    2018

    2018 marks the thirtieth anniversary of Regeneron’s founding

    FDA approves Libtayo? (cemiplimab-rwlc) , our seventh FDA-approved medicine

    The FDA approves a new indication for DUPIXENT? (dupilumab) Injection

    免费四虎库精品视倾